{
  "docId": "019de076-928b-754c-8bda-49c7fed3154d",
  "docSlug": "58a8f830d3c9f9a6fedd64a0d2a10227",
  "documentTitle": "ATAI | Investor Presentation Deck | 34 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 34,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide outlines two distinct study designs (COMP 005 and COMP 006) with specific primary endpoints at week 6.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-928b-754c-8bda-49c7fed3154d/16",
  "deckHref": "/decks/019de076-928b-754c-8bda-49c7fed3154d",
  "deckJsonHref": "/decks/019de076-928b-754c-8bda-49c7fed3154d.json",
  "deckAnchorHref": "/decks/019de076-928b-754c-8bda-49c7fed3154d#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.6,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "diagram",
      "text": "Pivotal Phase 3 Trial Designs",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a5158c58-a746-47ce-9565-b46dd753cc98",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.75,
        "y": 0.28
      },
      "kind": "list",
      "text": "Randomization = 2:1, Target N = 255, Topline data expected: summer-2024",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2088939c-7617-4053-b1fa-6754fe04576f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.75,
        "y": 0.68
      },
      "kind": "list",
      "text": "Randomization = 2:1:1, Target N = 568, Topline data expected: mid-2025",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4693af0e-c04d-448c-a890-239210d35f2f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.5,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Source: Compass Pathways Capital Markets Day presentation as of May 11th, 2023. 1. Primary endpoint = Change from baseline in MADRS total score at week 6. 2. The participant population (TRD definition and core inclusion / exclusion criteria) remains unchanged compared to Phase 2b",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "afb36601-9aa8-420e-872d-ae2c4aefaf78",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "COMPASS Pathways is currently conducting a Phase 3 pivotal program, with topline data expected in summer-2024 and mid-2025",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d67e0df-246d-4069-a2c7-f696fc130374",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "2b6ac0b3-4434-4227-9c94-fb29a6c851c7",
      "evidence": "Visual representation of clinical trial phases over time",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 16,
      "from": 5,
      "beatId": "09704901-0616-4280-b246-1ed7c74e3475",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The solution is presented through various product overviews and clinical evidence sections",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 34,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "c65cfc1b-596e-44b3-abf6-776a6539dcbf",
      "evidence": "The deck emphasizes the need for effective treatments",
      "position": 0,
      "objective": "Highlight the importance of addressing mental health disorders",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 34,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "7657d45c-02c7-40ab-9afc-a644dc2ed2c5",
      "evidence": "The deck follows a structure that aligns with the Golden Circle",
      "position": 1,
      "objective": "Explain the company's approach and solution",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}